Johansson S - Search Results

1

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.

Stack AG, Han D, Goldwater R, Johansson S, Dronamraju N, Oscarsson J, Johnsson E, Parkinson J, Erlandsson F. Stack AG, et al. Among authors: johansson s. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2347-e2356. doi: 10.1210/clinem/dgaa748. J Clin Endocrinol Metab. 2021. PMID: 33075806 Free PMC article. Clinical Trial.

2

Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.

Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Sokolov V, et al. Among authors: johansson s. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. doi: 10.1002/psp4.12498. Epub 2020 Mar 6. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32064793 Free PMC article.

3

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

Rekić D, Johansson S, Leander J. Rekić D, et al. Among authors: johansson s. Clin Pharmacokinet. 2021 Mar;60(3):319-328. doi: 10.1007/s40262-020-00943-6. Epub 2020 Sep 19. Clin Pharmacokinet. 2021. PMID: 32951150

4

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.

Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnsson E, Erlandsson F, Terkeltaub R. Stack AG, et al. Among authors: johansson s. Am J Kidney Dis. 2021 Apr;77(4):481-489. doi: 10.1053/j.ajkd.2020.09.009. Epub 2020 Oct 29. Am J Kidney Dis. 2021. PMID: 33130235 Free PMC article. Clinical Trial.

5

A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.

Leander J, Sunnåker M, Rekić D, Aksenov S, Eriksson UG, Johansson S, Parkinson J. Leander J, et al. Among authors: johansson s. J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):525-541. doi: 10.1007/s10928-021-09747-y. Epub 2021 Mar 17. J Pharmacokinet Pharmacodyn. 2021. PMID: 33728547 Free PMC article.

6

In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.

Gopaul VS, Vildhede A, Andersson TB, Erlandsson F, Lee CA, Johansson S, Hilgendorf C. Gopaul VS, et al. Among authors: johansson s. J Pharmacol Exp Ther. 2021 Aug;378(2):108-123. doi: 10.1124/jpet.121.000549. Epub 2021 Jun 1. J Pharmacol Exp Ther. 2021. PMID: 34074714

7

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants.

Johansson S, Han D, Hunt T, Björck K, Florica D, Gillen M, Hall J, Erlandsson F. Johansson S, et al. Pharmacol Res Perspect. 2022 Jun;10(3):e00929. doi: 10.1002/prp2.929. Pharmacol Res Perspect. 2022. PMID: 35593744 Free PMC article.

8

Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.

Parkinson J, Dota C, Källgren C, Gottfridsson C, Bjursell M, Perl S, Kӧrnicke T, Rekić D, Johansson S. Parkinson J, et al. Among authors: johansson s. Br J Clin Pharmacol. 2023 Jun;89(6):1747-1755. doi: 10.1111/bcp.15637. Epub 2023 Jan 2. Br J Clin Pharmacol. 2023. PMID: 36504291 Free article. Clinical Trial.

9

Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.

Samuelsson S, Johansson S, Halldórsdóttir S, Stenhoff H, Ohman KP. Samuelsson S, et al. Among authors: johansson s. J Clin Pharmacol. 2006 Sep;46(9):1017-22. doi: 10.1177/0091270006290335. J Clin Pharmacol. 2006. PMID: 16920896 Clinical Trial.

10

Prediction of drug-related morphological changes of the T wave.

Tjäderborn M, Aunes-Jansson M, Samuelsson E, Frison L, Johansson S, Berggren A, Edvardsson N. Tjäderborn M, et al. Among authors: johansson s. Scand Cardiovasc J. 2010 Aug;44(4):215-22. doi: 10.3109/14017431003789892. Scand Cardiovasc J. 2010. PMID: 20429697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,057 results

Search Page